Published in Int J Radiat Oncol Biol Phys on May 15, 2013
Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer. J Natl Cancer Inst (2015) 2.02
Quantifying Unnecessary Normal Tissue Complication Risks due to Suboptimal Planning: A Secondary Study of RTOG 0126. Int J Radiat Oncol Biol Phys (2015) 0.96
Impact of the introduction of weekly radiotherapy quality assurance meetings at one UK cancer centre. Br J Radiol (2014) 0.91
Value: a framework for radiation oncology. J Clin Oncol (2014) 0.88
Imaging and Data Acquisition in Clinical Trials for Radiation Therapy. Int J Radiat Oncol Biol Phys (2015) 0.82
Quality assurance for clinical trials. Front Oncol (2013) 0.81
Interobserver variability in radiation therapy plan output: Results of a single-institution study. Pract Radiat Oncol (2016) 0.78
Personalized radiotherapy: concepts, biomarkers and trial design. Br J Radiol (2015) 0.77
Implementation of a rapid learning platform: Predicting 2-year survival in laryngeal carcinoma patients in a clinical setting. Oncotarget (2016) 0.75
Quality assurance for the EORTC 22071-26071 study: dummy run prospective analysis. Radiat Oncol (2014) 0.75
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol (2010) 4.34
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys (2012) 2.55
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys (2011) 2.54
Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst (2013) 2.35
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol (2010) 2.12
Challenges in credentialing institutions and participants in advanced technology multi-institutional clinical trials. Int J Radiat Oncol Biol Phys (2008) 1.92
Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys (2009) 1.88
Standardizing naming conventions in radiation oncology. Int J Radiat Oncol Biol Phys (2012) 1.70
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol (2009) 1.33
QA makes a clinical trial stronger: evidence-based medicine in radiation therapy. Radiother Oncol (2012) 1.32
Variability of target volume delineation in cervical esophageal cancer. Int J Radiat Oncol Biol Phys (1998) 1.28
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol (2007) 1.26
Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st century. Radiother Oncol (2008) 1.10
Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med (1994) 1.07
Clinical impact of dosimetry quality assurance programmes assessed by radiobiological modelling of data from the thermoluminescent dosimetry study of the European Organization for Research and Treatment of Cancer. Eur J Cancer (2000) 1.04
Elapsed treatment days--a critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys (1991) 1.01
Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review. Radiother Oncol (2008) 1.00
The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC Phase III randomized trial 22922/10925 in Stage I--III breast cancer(1). Int J Radiat Oncol Biol Phys (2001) 0.95
Do results of the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials? Eur J Cancer (2012) 0.95
The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel. Strahlenther Onkol (2005) 0.94
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol (2001) 0.93
A glance on quality assurance in EORTC study 22922 evaluating techniques for internal mammary and medial supraclavicular lymph node chain irradiation in breast cancer. Radiother Oncol (2001) 0.91
Credentialing for participation in clinical trials. Front Oncol (2012) 0.89
Quality assurance for radiotherapy: a priority for clinical trials. J Natl Cancer Inst (2013) 0.89
Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes. Eur J Cancer (2007) 0.86
Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run. Radiother Oncol (2002) 0.85
Quality assurance of EORTC trial 22922/10925 investigating the role of internal mammary--medial supraclavicular irradiation in stage I-III breast cancer: the individual case review. Eur J Cancer (2003) 0.84
Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884). Int J Radiat Oncol Biol Phys (2005) 0.84
Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period. Radiother Oncol (2005) 0.83
Quality assurance in cancer treatment. Report of a Working Party from the European School of Oncology. Eur J Cancer (1993) 0.82
Quality assurance of the EORTC Trial 22881/10882: boost versus no boost in breast conserving therapy. An overview. Strahlenther Onkol (1997) 0.81
Quality assurance of radiotherapy in clinical trials. Cancer Treat Rep (1985) 0.81
Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review. Radiother Oncol (2012) 0.81
Impact of a dosimetry review program on radiotherapy in group trials. Int J Radiat Oncol Biol Phys (1985) 0.80
Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys (1996) 0.79
Protocol variations and their influence on the final outcome: critical review of the split-course base of tongue study of the RTOG. Int J Radiat Oncol Biol Phys (1985) 0.78
Quality control review for radiotherapy of small breast cancer: analysis of 708 patients in the GBSG I trial. German Breast Study Group (GBSG). Strahlenther Onkol (1993) 0.77
Radiotherapy review on national surgical adjuvant breast and bowel project (NSABP) phase III breast cancer clinical trials: is there a need for submission of portal/simulation films? Am J Clin Oncol (1999) 0.77
Patterns of care study: Hodgkin's disease relapse rates and adequacy of portals. Cancer (1983) 0.76
Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA (2010) 10.97
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol (2009) 3.99
Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys (2010) 3.87
Processes for quality improvements in radiation oncology clinical trials. Int J Radiat Oncol Biol Phys (2008) 2.25
Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys (2009) 1.88
Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer. Acta Oncol (2006) 1.77
A phase I/II trial to evaluate three-dimensional conformal radiation therapy confined to the region of the lumpectomy cavity for Stage I/II breast carcinoma: initial report of feasibility and reproducibility of Radiation Therapy Oncology Group (RTOG) Study 0319. Int J Radiat Oncol Biol Phys (2005) 1.76
Standardizing naming conventions in radiation oncology. Int J Radiat Oncol Biol Phys (2012) 1.70
Current calibration, treatment, and treatment planning techniques among institutions participating in the Children's Oncology Group. Int J Radiat Oncol Biol Phys (2003) 1.70
Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int J Radiat Oncol Biol Phys (2004) 1.42
Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys (2010) 1.35
The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys (2003) 1.32
Radiotherapy in pediatric medulloblastoma: quality assessment of Pediatric Oncology Group Trial 9031. Int J Radiat Oncol Biol Phys (2006) 1.32
Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group. J Clin Oncol (2006) 1.31
An evaluation of the relationship between the quality of prophylactic cranial radiotherapy in childhood acute leukemia and institutional experience: a Quality Assurance Review Center-Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys (2002) 1.27
Credentialing results from IMRT irradiations of an anthropomorphic head and neck phantom. Med Phys (2013) 1.23
A Monte Carlo model for calculating out-of-field dose from a varian 6 MV beam. Med Phys (2006) 1.19
A Monte Carlo model for out-of-field dose calculation from high-energy photon therapy. Med Phys (2007) 1.19
QA for helical tomotherapy: report of the AAPM Task Group 148. Med Phys (2010) 1.16
Experimental validation of deterministic Acuros XB algorithm for IMRT and VMAT dose calculations with the Radiological Physics Center's head and neck phantom. Med Phys (2012) 1.13
Influence of noncompliance with radiation therapy protocol guidelines and operative bed recurrences for children with rhabdomyosarcoma and microscopic residual disease: a report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys (2010) 1.10
Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study. Int J Radiat Oncol Biol Phys (2011) 1.02
Uncertainty of calculated risk estimates for secondary malignancies after radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.00
Monte Carlo study shows no significant difference in second cancer risk between 6- and 18-MV intensity-modulated radiation therapy. Radiother Oncol (2009) 0.94
Future vision for the quality assurance of oncology clinical trials. Front Oncol (2013) 0.93
Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803--a report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys (2011) 0.92
Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997. Pediatr Blood Cancer (2004) 0.91
Estimate of the uncertainties in the relative risk of secondary malignant neoplasms following proton therapy and intensity-modulated photon therapy. Phys Med Biol (2010) 0.91
Dosimetric impact of Acuros XB deterministic radiation transport algorithm for heterogeneous dose calculation in lung cancer. Med Phys (2013) 0.90
The clinical impact of the couch top and rails on IMRT and arc therapy. Phys Med Biol (2011) 0.89
Quality of radiotherapy reporting in randomized controlled trials of Hodgkin's lymphoma and non-Hodgkin's lymphoma: in regard to Bekelman and Yahalom (Int J Radiat Oncol Biol Phys 2009;73:492-498). Int J Radiat Oncol Biol Phys (2010) 0.89
The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803. Int J Radiat Oncol Biol Phys (2013) 0.88
The heat-shock factor is not activated in mammalian cells exposed to cellular phone frequency microwaves. Radiat Res (2005) 0.85
The age-related macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study. Am J Ophthalmol (2004) 0.85
Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia (2014) 0.84
The use of LiF (TLD-100) as an out-of-field dosimeter. J Appl Clin Med Phys (2007) 0.83
A six-year review of more than 13,000 patient-specific IMRT QA results from 13 different treatment sites. J Appl Clin Med Phys (2014) 0.81
Development and implementation of a remote audit tool for high dose rate (HDR) Ir-192 brachytherapy using optically stimulated luminescence dosimetry. Med Phys (2013) 0.81
Monitoring the effect of mild hyperthermia on tumour hypoxia by Cu-ATSM PET scanning. Int J Hyperthermia (2006) 0.81
Quality assurance of radiotherapy in the ongoing EORTC 22042-26042 trial for atypical and malignant meningioma: results from the dummy runs and prospective individual case Reviews. Radiat Oncol (2013) 0.79
Simultaneous radiotherapy and superficial hyperthermia for high-risk breast carcinoma: a randomised comparison of treatment sequelae in heated versus non-heated sectors of the chest wall hyperthermia. Int J Hyperthermia (2012) 0.79
In vivo CT dosimetry during CT colonography. AJR Am J Roentgenol (2014) 0.78
Effects of tertiary MLC configuration on secondary neutron spectra from 18 MV x-ray beams for the Varian 21EX linear accelerator. Med Phys (2009) 0.75
In regard to Urie et al.: current calibration treatment, and treatment planning techniques among institutions participating in the Children's Oncology Group. IJROBP 2003;55:245-260. Int J Radiat Oncol Biol Phys (2003) 0.75
Robert J. Shalek, Ph.D., J.D. Med Phys (2016) 0.75